The<unk>  rate within the first few months following a first episode of venous<unk>  (VTE) is not negligible.  In fact, it is estimated to be around 6% at 6 months following the first episode. Therefore, the duration of treatment with oral anticoagulation therapy must be long enough to decrease the risk of<unk>  while not too long to cause bleeding complications.  The duration of the treatment of oral anticoagulation is most problematic in the category of patients suffering from their first episode of unprovoked VTE; therefore, a marker of the risk of<unk>  of VTE in this population in particular is needed to tailor the duration of their treatment.
An association between changes in D-dimer levels during and following the discontinuation of oral anticoagulation and risk of<unk>  of VTE was suggested more than a decade ago, and the prognostic role of D-dimer in predicting the rate of<unk>  of VTE has been extensively studied.  Studies have been consistent in their findings of an association between elevated D-dimer levels and higher rates of<unk>  of VTE; as such, they suggest a possible role for D-dimer in predicting<unk>  of<unk>  and tailoring the duration of treatment of oral anticoagulation following VTE.  Resuming oral anticoagulation treatment (OAT) in subjects with abnormal D-dimer levels following the discontinuation of the OAT reduces their risk of VTE<unk> .
D-dimer prognostic role in thromboembolism recurrence
D-dimer prognostic role in thromboembolism occurrence
D-dimer diagnostic role in thromboembolism
D-dimer prognostic role in non thromboembolism conditions
D-dimer prognostic role in mortality
Portal vein thrombosis diagnostic study of choice
Portal hypertension diagnostic study of choice
Pulmonary hypertension diagnostic study of choice